June 2022
Volume 63, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2022
Adoptive Transfer of Plasmacytoid Dendritic Cells Promotes Allograft Survival in a Murine Allogeneic Corneal Transplantation
Author Affiliations & Notes
  • Fangfang Qiu
    Center for Translational Ocular Immunology, Department of Ophthalmology, Tufts Medical Center, Tufts University School of Medicine, Boston, Massachusetts, United States
  • Brendan Kenyon
    Center for Translational Ocular Immunology, Department of Ophthalmology, Tufts Medical Center, Tufts University School of Medicine, Boston, Massachusetts, United States
    Program in Neuroscience, Tufts University School of Graduate Biomedical Sciences, Boston, Massachusetts, United States
  • Cecilia Chao
    Center for Translational Ocular Immunology, Department of Ophthalmology, Tufts Medical Center, Tufts University School of Medicine, Boston, Massachusetts, United States
  • Deshea L Harris
    Center for Translational Ocular Immunology, Department of Ophthalmology, Tufts Medical Center, Tufts University School of Medicine, Boston, Massachusetts, United States
  • Olivia esteireiro
    Center for Translational Ocular Immunology, Department of Ophthalmology, Tufts Medical Center, Tufts University School of Medicine, Boston, Massachusetts, United States
  • Pedram Hamrah
    Center for Translational Ocular Immunology, Department of Ophthalmology, Tufts Medical Center, Tufts University School of Medicine, Boston, Massachusetts, United States
    Cornea Service, New England Eye Center; Department of Ophthalmology, Tufts Medical Center, Tufts University School of Medicine, Boston, Massachusetts, United States
  • Footnotes
    Commercial Relationships   Fangfang Qiu None; Brendan Kenyon None; Cecilia Chao None; Deshea Harris None; Olivia esteireiro None; Pedram Hamrah Kala, Novartis, Dompe, Clementia, Novaliq, Santen, Code C (Consultant/Contractor), Novartis, Oyster point, Dompe, Code S (non-remunerative)
  • Footnotes
    Support  NIH-R01-EY029602 (PH), NIH-R01-EY022695(PH), Research to Prevent Blindness Challenge Grant to the department of Ophthalmology, Massachusetts Lions Eye Research Fund, Inc (PH), Tufts Medical Center, Institutional Support (PH), and Eversight (PH).
Investigative Ophthalmology & Visual Science June 2022, Vol.63, 416. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Fangfang Qiu, Brendan Kenyon, Cecilia Chao, Deshea L Harris, Olivia esteireiro, Pedram Hamrah; Adoptive Transfer of Plasmacytoid Dendritic Cells Promotes Allograft Survival in a Murine Allogeneic Corneal Transplantation. Invest. Ophthalmol. Vis. Sci. 2022;63(7):416.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Graft rejection remains the leading cause of allograft failure in corneal transplantation. Plasmacytoid dendritic cells (pDCs) are implicated in the maintenance of immune tolerance in other models. Herein, we tested the hypothesis that adoptive transfer of pDCs can promote allograft survival via inducing immune tolerance, using an experimental allogenic corneal transplantation model

Methods : Allogenic corneal transplantation was established using BALB/c recipients and C57BL/6 donors. Adoptive transfer of sorted splenic allo-pDCs or saline were performed using fibrin sealant at d1 post-surgery. Anergic T cells, regulatory T cells (Tregs), Th1, and Th17 cells in draining lymph nodes (dLNs), and infiltrating leukocytes and T cells in corneas, were detected via flow cytometry at d14 post-transfer. Grafts was assessed twice weekly for 70 days with slit-lamp to score graft neovascularization (NV, 0-8+ scale), opacity (0-5+ scale), and rejection (graft opacity≥ score 3). Rejection-free graft survival was evaluated by Kaplan-Meier survival curves followed by log-rank test; unpaired t-test was used for comparisons.

Results : pDCs induced anergic CD4+T cells (CTLA-4+: 1.6-fold, PD-1+: 1.8-fold, LAG-3+: 4.6-fold, compared to the saline group; n=3, all p<0.05), and expanded the Foxp3+CD4+Tregs compartment (2.5-fold; n=3, p<0.001), while they had no effect on IFNγ+CD4+ Th1 and IL17+CD4+ Th17 (1.2-fold and 1.1-fold respectively; n=3, both p>0.05) in dLNs. In addition, pDCs ameliorated infiltration of CD45+ leukocytes and CD3+ T cells in corneal beds (CD45+: 87.5%, CD3+: 79.0% decrease compared to saline group; n=3, both p<0.05) and grafts (CD45+: 75.8%, CD3+: 71.9% decrease; n=3, both p<0.01). Moreover, pDCs suppressed corneal NV from d7 until d70 (score 2.8±0.34 SEM to 5.4±0.36, n=12 for pDCs transfer group vs 4.0±0.23 to 6.4±0.22, n=11 for saline control group; p<0.05 for all timepoints). Further, pDCs alleviated graft opacity from d14 until d70 (score 0.4±0.15 to 1.5±0.33, n=12 vs 1.1±0.21 to 3.5±0.45, n=11; all p<0.05), and improved survival rate of grafts (83.3%, n=12 vs 36.4%, n=11; p<0.01) through the end of 70 days.

Conclusions : Adoptive transfer of pDC promote survival of corneal allograft, which is associated with T cell tolerance, suggesting the translational potential of cell-based pDC therapy use in corneal transplantation

This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×